RTTNews | Oct 30, 2020 10:40AM EDT

10:40 Friday, October 30, 2020 (RTTNews.com) - Shares of Equillium, Inc. (EQ) are gaining more than 14 percent or $0.86 in Friday's morning trade at $6.86.

Thursday, Equillium said it has received FDA clearance to commence a phase III clinical trial of Itolizumab in hospitalized COVID-19 patients suffering from acute respiratory distress syndrome or ARDS. The company plans to begin patient enrollment in the trial named EQUINOX in the fourth quarter, with initial clinical data expected mid-year 2021.

Equillium has traded in a range of $2.20 to $27.05 in the past 52 weeks.

Read the original article on RTTNews ( https://www.rttnews.com/3141553/stock-alert-equillium-up-14-after-fda-clears-covid-19-trial-of-itolizumab.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2020 RTTNews.com All Rights Reserved